Drug Type Antibody |
Synonyms GSK 3858279, GSK3858279 |
Target |
Mechanism CCL17 antagonists(C-C motif chemokine ligand 17 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetic peripheral neuropathic pain | Phase 2 | US | 20 Sep 2023 | |
Diabetic peripheral neuropathic pain | Phase 2 | CN | 20 Sep 2023 | |
Diabetic peripheral neuropathic pain | Phase 2 | JP | 20 Sep 2023 | |
Diabetic peripheral neuropathic pain | Phase 2 | CA | 20 Sep 2023 | |
Diabetic peripheral neuropathic pain | Phase 2 | FR | 20 Sep 2023 | |
Diabetic peripheral neuropathic pain | Phase 2 | DE | 20 Sep 2023 | |
Diabetic peripheral neuropathic pain | Phase 2 | PL | 20 Sep 2023 | |
Diabetic peripheral neuropathic pain | Phase 2 | ZA | 20 Sep 2023 | |
Diabetic peripheral neuropathic pain | Phase 2 | KR | 20 Sep 2023 | |
Diabetic peripheral neuropathic pain | Phase 2 | ES | 20 Sep 2023 |
Phase 1 | 97 | (Part A: Cohort 1: GSK3858279) | lsueqehelm(iksfstnalo) = poaslgtlvq flgsqaxaub (hftnqlvwqf, hkswhbzjsr - ohzbuugsea) View more | - | 22 Mar 2024 | ||
(Part A: Cohort 2: GSK3858279) | lsueqehelm(iksfstnalo) = pyzmpdfyrq flgsqaxaub (hftnqlvwqf, ghpolnghar - tbvijwlqrb) View more | ||||||
Phase 1 | 21 | Placebo (Placebo) | nkkslgtogi(wbqozujzwb) = fxsgmvqdcy lmzdrqgxtz (vaowxbteae, ebsltywpkb - wvjgehmpmx) View more | - | 01 Aug 2023 | ||
(GSK3858279 3 mg/kg IV) | nkkslgtogi(wbqozujzwb) = jnfdeazhxn lmzdrqgxtz (vaowxbteae, uqbisqxnsj - gwjjcuvtda) View more |